Table 4 Biodistribution of 131I-ANA in different tissues of PC3 xenograft mice, N = 5 per condition.

From: Safety assessment, radioiodination and preclinical evaluation of antinuclear antibody as novel medication for prostate cancer in mouse xenograft model

Organ/tissue

% ID/g

6 h

24 h

48 h

72 h

168 h

Blood

4.48 ± 0.92**

3.69 ± 1.14

2.73 ± 0.45

1.68 ± 0.60****

1.44 ± 0.50**

Heart

1.25 ± 0.63

2.41 ± 2.23

3.57 ± 2.19

2.16 ± 0.52***

1.46 ± 0.99*

Liver

8.47 ± 1.88**

8.50 ± 1.45

7.11 ± 3.74

6.23 ± 1.64

4.22 ± 1.50

Lung

3.53 ± 2.01

2.88 ± 1.41

3.17 ± 1.07

2 ± 0.67***

0.67 ± 0.44**

Kidney

3.04 ± 0.51**

3.13 ± 1.93

2.98 ± 2.44

2.95 ± 0.19**

0.44 ± 0.20**

Spleen

0.98 ± 0.71

3.2 ± 2.71

4.34 ± 1.77

1.11 ± 0.48****

0.65 ± 0.46**

Intestine

5.51 ± 2.35

3.96 ± 2.36

2.86 ± 1.46

2.08 ± 0.88 **

0.51 ± 0.37**

Tumor

1.47 ± 0.40

4.69 ± 3.40

5.83 ± 3.24

5.13 ± 0.53

4.45 ± 1.03

Muscle

1.28 ± 0.30

4.09 ± 2.34

2.36 ± 0.20

2.01 ± 1.05**

0.84 ± 0.75**

Thyroid

4.14 ± 0.94*

1.56 ± 0.83

1.38 ± 0.81

1.20 ± 0.21***

1.17 ± 0.83**

T/B

0.33

1.27

2.14

3.05

3.10

T/L

0.17

0.55

0.82

0.82

1.06

T/K

0.48

1.50

1.96

1.74

10.14

T/M

1.15

1.15

2.47

2.55

5.32

T/Th

0.35

3.01

4.24

4.27

3.81

  1. Within the same column, asterisk (*) means that at the same time point post-injection, the levels of 131I-ANA in organs differ significantly from those in the tumors (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, one-way ANOVA tests with Dunnett's T3 multiple comparisons). Test details on 168 h: Tumor with blood (p = 0.076, t = 5.9) Tumor with heart (p = 0.012, t = 4.7), Tumor with lung (p = 0.0043, t = 7.5), Tumor with kidney (p = 0.006, t = 8.5), Tumor with intestine (p = 0.0031, t = 8.1). T/B, tumor to blood ratio; T/M, tumor to muscle ratio; T/L, tumor to liver ratio; T/K, tumor to kidney ratio; T/Th, tumor to thyroid ratio.
Back to article page